In vivo modeling of diffuse large B cell lymphoma (DLBCL) with the myeloid differentiation primary response gene 88 (MYD88) L265P mutationon

Diffuse large B cell lymphoma (DLBCL) is the most common lymphoid malignancy, accounting for 30–40% of adult lymphomas. It is a difficult-to-treat disease; only 60% of patients with DLBCL can achieve long-term remission with contemporary immune chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; or R-CHOP). Gene expression profiling has identified at least two biologically distinct DLBCL subtypes based on their cell of origin: the germinal center B cell-like (GCB) and the activated B cell-like (ABC) DLBCL (1).